ERBB2 and breast cancer: A few studies have suggested that the activation of an IL6 inflammatory loop through STAT3 mediates trastuzumab resistance in HER2-positive breast cancer by expanding the cancer stem cell population and by promoting epithelial-mesenchymal transition [21, 30, 31].